Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women. The company is also developing vaginal gel product candidate for the treatment of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EVFM
CUSIPN/A
Phone858-550-1900
Debt
Debt-to-Equity RatioN/A
Current Ratio0.27
Quick Ratio0.27
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.17 per share
Price / Book2.07
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-9,990,000.00
Net MarginsN/A
Return on Equity-134.38%
Return on Assets-1,071.45%
Miscellaneous
Employees23
Outstanding Shares26,260,000
Market Cap$63.29
Evofem Biosciences (NASDAQ:EVFM) Frequently Asked Questions
What is Evofem Biosciences' stock symbol?
Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."
How were Evofem Biosciences' earnings last quarter?
Evofem Biosciences Inc (NASDAQ:EVFM) announced its quarterly earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter. View Evofem Biosciences' Earnings History.
When is Evofem Biosciences' next earnings date?
What price target have analysts set for EVFM?
4 analysts have issued 12-month price objectives for Evofem Biosciences' stock. Their predictions range from $8.00 to $15.00. On average, they expect Evofem Biosciences' stock price to reach $10.75 in the next year. This suggests a possible upside of 344.2% from the stock's current price. View Analyst Ratings for Evofem Biosciences.
What is the consensus analysts' recommendation for Evofem Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Evofem Biosciences' key competitors?
Some companies that are related to Evofem Biosciences include Ovid Therapeutics (OVID), Avadel Pharmaceuticals (AVDL), resTORbio (TORC), Avid Bioservices (CDMO), Neptune Technologies & Bioressources (NEPT), REDHILL BIOPHAR/S (RDHL), Galmed Pharmaceuticals (GLMD), Cue Biopharma (CUE), ASLAN PHARMACEUTICALS ADR REP 5 (ASLN), Strongbridge Biopharma (SBBP), Ocular Therapeutix (OCUL), CTI BioPharma (CTIC), MannKind (MNKD), Galectin Therapeutics Inc. Common Stock (GALT) and Chimerix (CMRX).
Who are Evofem Biosciences' key executives?
Evofem Biosciences' management team includes the folowing people:
- Ms. Saundra Pelletier, CEO & Director
- Mr. Justin J. File, Chief Financial Officer
- Dr. Kelly Culwell, Chief Medical Officer
- Mr. Alexander A. Fitzpatrick, Gen. Counsel & Sec. (Age 51)
- Mr. Russell Barrans, Chief Commercial Officer
Has Evofem Biosciences been receiving favorable news coverage?
News stories about EVFM stock have been trending somewhat positive on Wednesday, Accern reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Evofem Biosciences earned a media sentiment score of 0.12 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.18 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Evofem Biosciences' major shareholders?
How do I buy shares of Evofem Biosciences?
Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Evofem Biosciences' stock price today?
One share of EVFM stock can currently be purchased for approximately $2.42.
How big of a company is Evofem Biosciences?
Evofem Biosciences has a market capitalization of $63.29 million. Evofem Biosciences employs 23 workers across the globe.
How can I contact Evofem Biosciences?
Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected]
MarketBeat Community Rating for Evofem Biosciences (NASDAQ EVFM)
MarketBeat's community ratings are surveys of what our community members think about Evofem Biosciences and other stocks. Vote "Outperform" if you believe EVFM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVFM will underperform the S&P 500 over the long term. You may vote once every thirty days.
